EPS for Rhythm Pharmaceuticals, Inc. (RYTM) Expected At $-0.45

May 17, 2018 - By Ash Ash

Analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to report $-0.45 EPS on June, 11.After having $-0.41 EPS previously, Rhythm Pharmaceuticals, Inc.’s analysts see 9.76 % EPS growth. The stock increased 3.57% or $1.1 during the last trading session, reaching $31.88. About 144,968 shares traded or 42.14% up from the average. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $877.26 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were published by: Nasdaq.com which released: “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” on May 09, 2018. Also Globenewswire.com published the news titled: “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results” on May 14, 2018. Nasdaq.com‘s news article titled: “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” with publication date: May 09, 2018 was also an interesting one.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.